This ASX 200 healthcare share just hit a new 52-week high. Here's why

The ASX 200 health imaging company is edging back towards its all-time highs.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • The Pro Medicus share price just hit fresh 52-week highs
  • The ASX 200 healthcare share announced a $25 million contract with the University of Washington’s UW Medicine health system
  • Planning for the cloud-based rollout will start immediately

S&P/ASX 200 Index (ASX: XJO) healthcare share Pro Medicus Ltd (ASX: PME) is marching higher today, up 1.51% at the time of writing.

That sees the healthcare stock trading for $63.06 per share after hitting $63.35 late this morning, a fresh 52-week high. It's also now less than 4% below the all-time Pro Medicus share price high, reached in August 2021.

four excited doctors with their hands in the air

Image source: Getty Images

What's sending the ASX 200 healthcare share higher?

Investors are rewarding Pro Medicus after the health imaging company announced on Friday that Visage Imaging, its 100% owned United States subsidiary, signed a $25 million, seven-year contract with the University of Washington's UW Medicine health system.

UW Medicine employs 29,000 healthcare professionals, researchers, and educators.

The ASX 200 healthcare share reported UW Medicine will implement its cloud-engineered Visage 7 Enterprise Imaging Platform throughout its network "providing a unified diagnostic imaging platform".

Planning for the cloud-based rollout will start immediately. Pro Medicus expects the first go-lives to commence in the second half of 2023.

Commenting on the contract, Pro Medicus CEO Sam Hupert said:

UW Medicine joins our growing list of Tier 1 academic clients and will provide us with a strong presence in the Northwest region of the United States. With its highly regarded University of Washington School of Medicine, it has the added benefit of exposing Visage to an ever-increasing number of the doctors of tomorrow.

Hupert noted that the contract encompasses all Pro Medicus Visage products.

"Our pipeline remains strong and spans all market segments," he said. "And as has been the case with many of our recent sales, this deal is for our 'full-stack' comprising all three Visage products namely viewer, workflow and archive, a trend we see continuing."

Pro Medicus share price snapshot

As you can see in the chart below, the Pro Medicus share price strongly outperformed over the past 12 months, gaining 40% compared to a 4% gain posted by the ASX 200.

Investors who bought into the ASX 200 healthcare share five years ago will be sitting on some superbly healthy gains of 683%.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

Starpharma: FY26 earnings reveal strong revenue growth and improved loss

Starpharma posted a sharp rise in FY26 revenue and narrowed its loss, with new funds extending its cash runway into…

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

Could this ASX biotech really jump more than 500%?

This company is in the ramp up phase.

Read more »

Happy, tablet or doctor in a laboratory with research results or positive feedback after medical data analysis. Smile, vaccine or healthcare worker reading or working on futuristic science innovation.
Earnings Results

Neuren Pharmaceuticals reports lower profit but launches first dividend

The pharmaceuticals company is returning funds to shareholders with its first ever dividend.

Read more »

A scientist examining test results.
Healthcare Shares

PolyNovo FY26 earnings: Revenue jumps, profit steady

PolyNovo posted double-digit revenue growth and positive profit for FY26, as manufacturing expansion and global reach supported its medtech ambitions.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Broker Notes

Bell Potter says this ASX biotech could nearly double in value

The US market is starting to open up for this company.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Integral Diagnostics posts profit and dividend growth in FY26

Integral Diagnostics FY26 earnings show revenue and profit growth, higher dividend, and a positive outlook for investors.

Read more »

A scientist in a white coat and glasses puts her arms in the air in a sign of strength and success.
Broker Notes

This ASX small-cap healthcare stock is tipped to double in value

This company has a good base to build on.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Neuren share price in focus after DAYBU wins EU approval for Rett syndrome

Neuren shares are on watch after DAYBU (trofinetide) won European approval, unlocking commercial milestones and revenue opportunities.

Read more »